Aims The aim of this article is to explore the influence of region and race/ethnicity on the
effects of empagliflozin in the Empagliflozin Outcome Trial in Patients with Chronic Heart …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Hypertension (HT) is an important risk factor for heart failure (HF). The prevalence of HT
among the HF population is higher in Asia than in other regions around the world. In Asia …

Heart Failure is a crippling condition with a very poor outcome. Advanced heart failure is the
endpoint in patients of heart failure. Mortality rates are significantly higher among these …

Objectives The primary aim of the current study was to investigate global differences in
prevalence, association with outcome, and treatment of ischemic heart disease (IHD) in …

Background: Little is known regarding the impact of socioeconomic factors on the use of
evidence-based therapies and outcomes in patients with heart failure with reduced ejection …

Background Data on rehospitalizations for heart failure (HF) in Asia are scarce. We sought to
determine the burden and predictors of HF (first and recurrent) rehospitalizations and all …

Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older
patients with heart failure has not been explored. We aimed to investigate the risk of …

Aim We aim to determine the cost‐effectiveness of dapagliflozin in addition to standard
therapy versus standard therapy alone among patients with heart failure with reduced …

Background Frailty is common in patients with heart failure (HF) and can adversely impact
outcomes. Objectives This study examined the prevalence of frailty among Asian patients …